BETA


2006/2161(DEC) 2005 discharge: European Agency for the Evaluation of Medicinal Products

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead CONT HERCZOG Edit (icon: PSE PSE)
Committee Opinion ENVI HAUG Jutta (icon: PSE PSE)
Lead committee dossier:
Legal Basis:
RoP 100

Events

2008/07/15
   Final act published in Official Journal
Details

PURPOSE: to grant discharge to the European Medicines Agency for the financial year 2005.

LEGISLATIVE ACT: Decision 2008/521/EC of the European Parliament on the discharge for the implementation of the budget of the European Medicines Agency for the financial year 2005.

CONTENT: with the present decision, the European Parliament grants discharge to the Executive Director of the European Medicines Agency for the implementation of the Agency’s budget for the financial year 2005.

This decision is in line with the European Parliament’s resolution adopted on 24 April 2007 and comprises a series of observations that form an integral part of the discharge decision (please refer to the summary of the opinion of 24/04/2007).

2007/05/31
   EC - Commission response to text adopted in plenary
Documents
2007/04/24
   EP - Results of vote in Parliament
2007/04/24
   EP - Debate in Parliament
2007/04/24
   EP - Decision by Parliament
Details

The European Parliament adopted a resolution drafted by Edit HERCZOG (PSE, HU), and granted the executive director of the European Medicines Agency discharge for the implementation of the Agency's budget for the financial year 2005. It then approved the closing of the accounts of the Centre for the financial year 2005.

The Parliamentary resolution is divided into two parts. The first contained general points, and concerned the majority of EU Agencies requiring individual discharge. The second part contained specific points relating to the Agency.

General points: Parliament considers that the ever-growing number of Community Agencies and the activities of certain of them do not seem to form part of an overall policy framework, and that the remits of some Agencies do not always reflect the real needs of the Union. Accordingly, it invites the Commission to define an overall policy framework for the setting up of new Community Agencies and to present a cost-benefit study before the setting up of any new agency, while being careful to avoid any overlap of activities between Agencies or with the remits of other European organisations. Parliament calls on the Court of Auditors to give its opinion on this cost-benefit study before Parliament takes its decision, and it asks the Commission to present every five years a study on the added value of every existing Agency. ; invites all relevant institutions In the case of a negative evaluation of the added value of an Agency, all relevant institutions are asked to take the necessary steps by reformulating the mandate of that Agency or by closing it.

In view of the constantly increasing number of Agencies, Parliament feels that the Directorates-General of the Commission charged with the setting up and monitoring of Agencies must develop a common approach to the Agencies. It also asks the Commission to improve administrative and technical support to the Agencies. Parliament regretted that the negotiations on the draft interinstitutional agreement on the operating framework for the European regulatory agencies have not yet been concluded, and calls on the Commission, in consultation with the Court of Auditors, to do their utmost to ensure that the agreement is brought to a rapid conclusion. Noting that the Commission's budgetary responsibility calls for closer linking of the Agencies to the Commission, Parliament calls on the Commission and the Council to take all necessary steps to give the Commission a blocking minority in the supervisory bodies of the regulatory Agencies by 31 December 2007 and to provide for such a minority from the outset when new Agencies are set up. It invites the Court of Auditors to create an additional chapter in its Annual Report, devoted to all Agencies to be discharged under the Commission's accounts in order to have a much clearer picture of the use of EU funds by Agencies.

Parliament goes on to ask the Commission to come up with a proposal to harmonise the format of the annual reporting by the Agencies and to develop performance indicators which would allow a comparison of their efficiency. The Commission is urged to monitor and direct the management of the Agencies, especially in relation to the proper application of tender procedures, transparency of recruitment procedures, sound financial management and, most importantly, the proper application of the rules concerning the internal control framework.

Specific points concerning the European Medicines Agency: Parliament noted that for administrative expenditure (Title II) the utilisation rate for commitment appropriations was less than 90 %, with more than 40 % of the commitments made being carried over to the following financial year. It also noted that the budget of the Agency has grown considerably between 2003 and 2005 due to the enlargement of the EU and new tasks, and pronounced itself very pleased with the increased appropriations for, and the full implementation of, the Orphan Drugs budget line. Parliament invited the Agency to make sure that only staff members with delegation rights have access to the corresponding computer system. It demanded that contract award procedures should be transparent and follow the guiding rules including in the IT area, and it asked the Agency to inform Parliament about the new call for tender concerning bank contracts according to standard rules as soon as possible.

Parliament went on to point out that the new pharmaceuticals legislation, adopted in 2004, has had a considerable impact on the Agency's work, management structures and staff, congratulating the Agency on successfully adapting to the new regulatory framework. It welcomed the Agency’s efforts to provide more scientific advice at early stages of the development of new medicines as well as the introduction of measures to accelerate the assessment of medicines that are of critical importance to public health, noting the work done by the Agency to facilitate a quick assessment of vaccines in the event of an influenza pandemic.

Lastly, Parliament wanted the Agency to commission an independent external evaluation of its achievements before 1 January 2010 and every five years thereafter. The Agency should draft such recommendations to the Commission and Parliament as may be necessary regarding changes in the Agency. The evaluation and the recommendations must be made public.

Documents
2007/04/24
   EP - End of procedure in Parliament
2007/03/30
   EP - Committee report tabled for plenary, single reading
Documents
2007/03/30
   EP - Committee report tabled for plenary
Documents
2007/03/26
   EP - Vote in committee
Details

The committee adopted the report by Edit HERCZOG (PES, HU) granting discharge to the the European Medicines Agency for 2005. In its accompanying resolution, it made a number of general points concerning the majority of the EU agencies:

- the ever-growing number of Community Agencies and the activities of some of them do not seem to form part of an overall policy framework, and "the remits of some Agencies do not always reflect the real needs of the Union or the expectations of its citizens”;

- the Commission should therefore define an overall policy framework and should present a cost-benefit study before the setting up of any new Agency, and the Court of Auditors should give its opinion on this study before Parliament takes its decision;

- every 5 years, the Commission should present a study on the added value of every existing Agency; where the evaluation is negative in the case of a particular Agency the latter’s mandate should be reformulated or the Agency should be closed;

- the Commission should improve administrative and technical support to the Agencies, given the growing complexity of the Community’s administrative rules and technical problems;

- the Agencies should improve their cooperation and benchmarking with actors in the field;

- the Commission should harmonise the format of the annual reporting by the Agencies to develop performance indicators which would allow a comparison of their efficiency.

In its specific remarks concerning the EMA, the committee welcomed the increased appropriations for and full implementation of the Orphan Drugs budget line. It pointed out that the new pharmaceuticals legislation adopted in 2004 had had a considerable impact on the Agency's work, management structures and staff, and it welcomed the Agency's efforts to provide more scientific advice at early stages of the development of new medicines. It also noted the Agency's work in facilitating a quick assessment of vaccines in the event of an influenza pandemic. Lastly, the committee asked the Agency, before 1 January 2010 and every 5 years thereafter, to commission an independent external evaluation of its achievements on the basis of its founding Regulation and the work programmes decided by the Management Board. In the light of this evaluation, the Board should draft "such recommendations to the Commission and Parliament as may be necessary regarding changes in the Agency, its working practices and programmes".

2007/03/08
   EP - Amendments tabled in committee
Documents
2007/02/28
   EP - Committee opinion
Documents
2007/02/27
   CSL - Council Meeting
2007/02/09
   EP - Committee draft report
Documents
2007/02/07
   CSL - Supplementary non-legislative basic document
Details

Having examined the revenue and expenditure account for the financial year 2005, the balance sheet of revenue and expenditure at 31 December 2005 of the European Medicines Agency, the Council recommends the European Parliament to give a discharge to the Director of the Agency in respect of the implementation of the budget for the financial year 2005.

In doing so, the Council confirms that EUR 21.6 million (95%) of the EUR 22.7 million in appropriations carried forward from the financial year 2004 to the financial year 2005 have been used. In addition, EUR 18.8 million in appropriations have been carried forward from the financial year 2005 to the financial year 2006 and EUR 5.6 million have been cancelled.

In parallel, the Council makes accompanying comments on the discharge which should be followed up. In particular, it:

shares the Court's observation on the high carry-over rate for administrative expenditure in 2004-2005 and calls on the Agency to comply with the principle of annuality; calls on the Agency to respect the rules on the award of contracts, especially as regards IT contracts; shares the Court's opinion on the need to start a new call for tender regarding the services provided by banks and notes from the Agency's reply that this is the case.

Documents
2006/12/19
   CofA - Court of Auditors: opinion, report
Details

This report from the Court of Auditors concerns the results of the audit carried out by the Court on the annual accounts of the European Medicines Agency for the financial year ended 31 December 2005.

The Court states that its audit was planned and performed to obtain reasonable assurance that the accounts are reliable and the underlying transactions are legal and regular.

The report shows that the appropriations entered in the final budget amount to EUR 111 835 000 with EUR 105 354 000 committed and EUR 88 489 000 paid. EUR 18 833 000 was carried over to 2006, and EUR 4 513 000 cancelled.

In its report, the Court observes that the utilisation rates for commitment appropriations (94 %) and payment appropriations (82 %) were on the whole high. For administrative expenditure (Title II), however, the utilisation rate for commitment appropriations was less than 90 %, and more than 40 % of the commitments made were carried over to the following financial year.

Other observations are as follows:

access rights to the computer system did not always correspond to the delegations in force; from the end of 2004, the Agency has managed funds (approximately EUR 400 000) collected from other Agencies and bodies to finance a common support service to develop their financial management information systems. Up to 2005, these funds were not presented in the Agency’s annual accounts, as was the case with other Agencies which managed the funds in earlier years following a rotational system; anomalies were found in the course of checks on the award of contracts, especially as regards IT contracts; no formal decisions concerning the appointment of evaluation committees; rules governing the hierarchical independence of committee members were not observed; evaluation committee meetings were held in the absence of some of the members, without any formal justification for their absence; contracts concluded with the banks have been in force for over six years even though the detailed rules for the implementation of the Agency’s financial regulation lay down that there should be a new call for tenders at least once every five years.

The Agency responds point by point to the Court’s observations. It notes that the high carry-over 2004-2005 on Title 2 is mainly due to the Telematics expenditure programme, which accounts for 80 % of the carry-overs. The Telematics carry-overs were high because this programme comprises a number of large and complex multi-annual projects covering the whole EU that stretched from 2004 through into 2005.

Security access has been rectified and all delegated authorising officers were instructed that they must take care to sign the right transaction (in SI2) based on the delegation decision and that they must act with due diligence in this regard.

The CSS expenditure for 2006 will be included in the EMEA budget with the first Amending Budget and the costs will be charged to the members. Disclosure of the CSS activities in 2005 has been made in note 4 of the EMEA 2005 Accounts.

The composition of evaluation committees, often made up of more than three persons, is based on the principle that bids should be evaluated by persons both independent and with appropriate expertise. In any case, a minimum of three persons participate to the meetings and the minutes for each meeting are distributed for discussion and approval. In the future, the Agency will request that minutes include a justification in case of absence of a member.

Lastly, in 2006, the Agency launched a tender for banking services. The delay mentioned by the Court is due to the fact that over the last years, the financial system of the Agency has been overhauled and it would have been too disruptive to implement a change of bank.

2006/11/29
   EP - Committee referral announced in Parliament
2006/10/31
   OS - Non-legislative basic document
Details

PURPOSE: presentation of the final accounts of the European Medicines Agency for the financial year 2005.

CONTENT: this document published in the Official Journal of the EU sets out a detailed account of the implementation of the 2005 budget, including the revenue and expenditure and the balance sheet for the year concerned.

According to this document, the final budget amounted to EUR 111.8 million (in comparison to EUR 99.4 million in 2004) consisting of a 22.7% Community contribution.

As regards staffing, the Agency, whose headquarters are based in London (UK), set out a total of 379 posts in the establishment plan. 337.5 posts are currently occupied + 34 other posts (auxiliary contracts, seconded national experts, local staff, employment agency staff) totalling 317.5 posts (340 in 2004) assigned to operational, administrative and mixed tasks.

Staff expenditure accounted for EUR 41.356 million.

Throughout 2005, the Agency concentrated on coordinating the scientific evaluation of medicinal products which are subject to Community marketing authorisation procedures.

Concerning medicinal products for human use, the Agency:

- replied to 43 applications for marketing authorisations and delivered 24 favourable opinions taking an average evaluation time of 203 days as opposed to 187 days in 2004;

- delivered 1 148 opinions after authorisation;

- drafted 91 565 pharmacovigilance reports (64 186 in 2004) and 279 periodic reliability reports;

- delivered 135 scientific opinions and 8 451 procedures for mutual recognition.

Concerning veterinary medicinal products, the Agency:

- replied to 11 new applications for marketing authorisations and 70 applications in respect of variants;

- carried out 114 inspections.

As regards orphan medicinal products, the Agency:

- replied to 118 applications and gave 88 favourable opinions.

The complete version of the final accounts may be found at the following address:

www.emea.eu.int

2006/10/30
   EC - Non-legislative basic document published
Details

PURPOSE: presentation of the final accounts of the European Medicines Agency for the financial year 2005.

CONTENT: this document published in the Official Journal of the EU sets out a detailed account of the implementation of the 2005 budget, including the revenue and expenditure and the balance sheet for the year concerned.

According to this document, the final budget amounted to EUR 111.8 million (in comparison to EUR 99.4 million in 2004) consisting of a 22.7% Community contribution.

As regards staffing, the Agency, whose headquarters are based in London (UK), set out a total of 379 posts in the establishment plan. 337.5 posts are currently occupied + 34 other posts (auxiliary contracts, seconded national experts, local staff, employment agency staff) totalling 317.5 posts (340 in 2004) assigned to operational, administrative and mixed tasks.

Staff expenditure accounted for EUR 41.356 million.

Throughout 2005, the Agency concentrated on coordinating the scientific evaluation of medicinal products which are subject to Community marketing authorisation procedures.

Concerning medicinal products for human use, the Agency:

- replied to 43 applications for marketing authorisations and delivered 24 favourable opinions taking an average evaluation time of 203 days as opposed to 187 days in 2004;

- delivered 1 148 opinions after authorisation;

- drafted 91 565 pharmacovigilance reports (64 186 in 2004) and 279 periodic reliability reports;

- delivered 135 scientific opinions and 8 451 procedures for mutual recognition.

Concerning veterinary medicinal products, the Agency:

- replied to 11 new applications for marketing authorisations and 70 applications in respect of variants;

- carried out 114 inspections.

As regards orphan medicinal products, the Agency:

- replied to 118 applications and gave 88 favourable opinions.

The complete version of the final accounts may be found at the following address:

www.emea.eu.int

Documents
2006/09/14
   EP - HAUG Jutta (PSE) appointed as rapporteur in ENVI
2006/04/20
   EP - HERCZOG Edit (PSE) appointed as rapporteur in CONT

Documents

History

(these mark the time of scraping, not the official date of the change)

docs/1/docs/1/url
Old
https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:2006:312:SOM:EN:HTML
New
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2006:312:TOC
docs/4/docs/0/url
https://www.europarl.europa.eu/doceo/document/ENVI-AD-382438_EN.html
docs/7/docs/0/url
/oeil/spdoc.do?i=13464&j=0&l=en
events/0/date
Old
2006-10-31T00:00:00
New
2006-10-30T00:00:00
events/8/docs/1/url
Old
https://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2008:187:SOM:EN:HTML
New
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2008:187:TOC
docs/0
date
2006-10-31T00:00:00
docs
summary
type
Non-legislative basic document
body
OS
docs/0
date
2006-10-31T00:00:00
docs
summary
type
Non-legislative basic document
body
OS
docs/1
date
2006-12-19T00:00:00
docs
summary
type
Court of Auditors: opinion, report
body
CofA
docs/1
date
2006-12-19T00:00:00
docs
summary
type
Court of Auditors: opinion, report
body
CofA
docs/3/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE384.440
New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE384.440
docs/4/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE382.438&secondRef=02
docs/5/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE386.407
New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE386.407
docs/6/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-6-2007-0099_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-6-2007-0099_EN.html
events/0/docs/0/url
https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:[%SECTOR]2006[%DESCRIPTOR]0029:EN:NOT
events/1/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament
events/2/type
Old
Vote in committee, 1st reading/single reading
New
Vote in committee
events/3
date
2007-03-30T00:00:00
type
Committee report tabled for plenary
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-6-2007-0099_EN.html title: A6-0099/2007
events/3
date
2007-03-30T00:00:00
type
Committee report tabled for plenary, single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/A-6-2007-0099_EN.html title: A6-0099/2007
events/5/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20070424&type=CRE
New
https://www.europarl.europa.eu/doceo/document/EN&reference=20070424&type=CRE
events/6
date
2007-04-24T00:00:00
type
Decision by Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-6-2007-0120_EN.html title: T6-0120/2007
summary
events/6
date
2007-04-24T00:00:00
type
Decision by Parliament, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/TA-6-2007-0120_EN.html title: T6-0120/2007
summary
events/8
date
2008-07-15T00:00:00
type
Final act published in Official Journal
summary
docs
events/8
date
2008-07-15T00:00:00
type
Final act published in Official Journal
summary
docs
procedure/final/url
Old
http://www.europarl.europa.eu/doceo/document/B-2-21-08B0_EN.html
New
https://www.europarl.europa.eu/doceo/document/B-2-21-08B0_EN.html
procedure/legal_basis/0
Rules of Procedure EP 100
procedure/legal_basis/0
Rules of Procedure EP 94
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Budgetary Control
committee
CONT
rapporteur
name: HERCZOG Edit date: 2006-04-20T00:00:00 group: Socialist Group in the European Parliament abbr: PSE
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Budgetary Control
committee
CONT
date
2006-04-20T00:00:00
rapporteur
name: HERCZOG Edit group: Socialist Group in the European Parliament abbr: PSE
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: HAUG Jutta date: 2006-09-14T00:00:00 group: Socialist Group in the European Parliament abbr: PSE
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2006-09-14T00:00:00
rapporteur
name: HAUG Jutta group: Socialist Group in the European Parliament abbr: PSE
docs/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2007-99&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-6-2007-0099_EN.html
docs/7/body
EC
events/3/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2007-99&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-6-2007-0099_EN.html
events/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P6-TA-2007-120
New
http://www.europarl.europa.eu/doceo/document/TA-6-2007-0120_EN.html
events/8
date
2008-07-15T00:00:00
type
Final act published in Official Journal
summary
docs
events/8
date
2008-07-15T00:00:00
type
Final act published in Official Journal
summary
docs
procedure/final/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B[%g]-2008-521&language=EN
New
http://www.europarl.europa.eu/doceo/document/B-2-21-08B0_EN.html
activities
  • date: 2006-10-31T00:00:00 docs: type: Non-legislative basic document published title: N6-0029/2006 body: EC commission: DG: url: http://ec.europa.eu/dgs/budget/ title: Budget Commissioner: KALLAS Siim type: Non-legislative basic document published
  • date: 2006-11-29T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: CONT date: 2006-04-20T00:00:00 committee_full: Budgetary Control rapporteur: group: PSE name: HERCZOG Edit body: EP responsible: False committee: ENVI date: 2006-09-14T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PSE name: HAUG Jutta
  • date: 2007-02-27T00:00:00 body: CSL type: Council Meeting council: Economic and Financial Affairs ECOFIN meeting_id: 2787
  • date: 2007-03-26T00:00:00 body: EP committees: body: EP responsible: True committee: CONT date: 2006-04-20T00:00:00 committee_full: Budgetary Control rapporteur: group: PSE name: HERCZOG Edit body: EP responsible: False committee: ENVI date: 2006-09-14T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PSE name: HAUG Jutta type: Vote in committee, 1st reading/single reading
  • date: 2007-03-30T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2007-99&language=EN type: Committee report tabled for plenary, single reading title: A6-0099/2007 body: EP type: Committee report tabled for plenary, single reading
  • date: 2007-04-24T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=13464&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20070424&type=CRE type: Debate in Parliament title: Debate in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P6-TA-2007-120 type: Decision by Parliament, 1st reading/single reading title: T6-0120/2007 body: EP type: Results of vote in Parliament
  • date: 2008-07-15T00:00:00 type: Final act published in Official Journal docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B[%g]-2008-521&language=EN title: Budget 2008/521 url: http://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2008:187:SOM:EN:HTML title: OJ L 187 15.07.2008, p. 0128
commission
  • body: EC dg: Budget commissioner: KALLAS Siim
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Budgetary Control
committee
CONT
date
2006-04-20T00:00:00
rapporteur
name: HERCZOG Edit group: Socialist Group in the European Parliament abbr: PSE
committees/0
body
EP
responsible
True
committee
CONT
date
2006-04-20T00:00:00
committee_full
Budgetary Control
rapporteur
group: PSE name: HERCZOG Edit
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2006-09-14T00:00:00
rapporteur
name: HAUG Jutta group: Socialist Group in the European Parliament abbr: PSE
committees/1
body
EP
responsible
False
committee
ENVI
date
2006-09-14T00:00:00
committee_full
Environment, Public Health and Food Safety
rapporteur
group: PSE name: HAUG Jutta
council
  • body: CSL type: Council Meeting council: Economic and Financial Affairs ECOFIN meeting_id: 2787 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2787*&MEET_DATE=27/02/2007 date: 2007-02-27T00:00:00
docs
  • date: 2006-10-31T00:00:00 docs: url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2006:266:TOC title: OJ C 266 31.10.2006, p. 0004 title: N6-0029/2006 summary: PURPOSE: presentation of the final accounts of the European Medicines Agency for the financial year 2005. CONTENT: this document published in the Official Journal of the EU sets out a detailed account of the implementation of the 2005 budget, including the revenue and expenditure and the balance sheet for the year concerned. According to this document, the final budget amounted to EUR 111.8 million (in comparison to EUR 99.4 million in 2004) consisting of a 22.7% Community contribution. As regards staffing, the Agency, whose headquarters are based in London (UK), set out a total of 379 posts in the establishment plan. 337.5 posts are currently occupied + 34 other posts (auxiliary contracts, seconded national experts, local staff, employment agency staff) totalling 317.5 posts (340 in 2004) assigned to operational, administrative and mixed tasks. Staff expenditure accounted for EUR 41.356 million. Throughout 2005, the Agency concentrated on coordinating the scientific evaluation of medicinal products which are subject to Community marketing authorisation procedures. Concerning medicinal products for human use, the Agency: - replied to 43 applications for marketing authorisations and delivered 24 favourable opinions taking an average evaluation time of 203 days as opposed to 187 days in 2004; - delivered 1 148 opinions after authorisation; - drafted 91 565 pharmacovigilance reports (64 186 in 2004) and 279 periodic reliability reports; - delivered 135 scientific opinions and 8 451 procedures for mutual recognition. Concerning veterinary medicinal products, the Agency: - replied to 11 new applications for marketing authorisations and 70 applications in respect of variants; - carried out 114 inspections. As regards orphan medicinal products, the Agency: - replied to 118 applications and gave 88 favourable opinions. The complete version of the final accounts may be found at the following address: www.emea.eu.int type: Non-legislative basic document body: OS
  • date: 2006-12-19T00:00:00 docs: url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:2006:312:SOM:EN:HTML title: OJ C 312 19.12.2006, p. 0001 title: N6-0001/2007 summary: This report from the Court of Auditors concerns the results of the audit carried out by the Court on the annual accounts of the European Medicines Agency for the financial year ended 31 December 2005. The Court states that its audit was planned and performed to obtain reasonable assurance that the accounts are reliable and the underlying transactions are legal and regular. The report shows that the appropriations entered in the final budget amount to EUR 111 835 000 with EUR 105 354 000 committed and EUR 88 489 000 paid. EUR 18 833 000 was carried over to 2006, and EUR 4 513 000 cancelled. In its report, the Court observes that the utilisation rates for commitment appropriations (94 %) and payment appropriations (82 %) were on the whole high. For administrative expenditure (Title II), however, the utilisation rate for commitment appropriations was less than 90 %, and more than 40 % of the commitments made were carried over to the following financial year. Other observations are as follows: access rights to the computer system did not always correspond to the delegations in force; from the end of 2004, the Agency has managed funds (approximately EUR 400 000) collected from other Agencies and bodies to finance a common support service to develop their financial management information systems. Up to 2005, these funds were not presented in the Agency’s annual accounts, as was the case with other Agencies which managed the funds in earlier years following a rotational system; anomalies were found in the course of checks on the award of contracts, especially as regards IT contracts; no formal decisions concerning the appointment of evaluation committees; rules governing the hierarchical independence of committee members were not observed; evaluation committee meetings were held in the absence of some of the members, without any formal justification for their absence; contracts concluded with the banks have been in force for over six years even though the detailed rules for the implementation of the Agency’s financial regulation lay down that there should be a new call for tenders at least once every five years. The Agency responds point by point to the Court’s observations. It notes that the high carry-over 2004-2005 on Title 2 is mainly due to the Telematics expenditure programme, which accounts for 80 % of the carry-overs. The Telematics carry-overs were high because this programme comprises a number of large and complex multi-annual projects covering the whole EU that stretched from 2004 through into 2005. Security access has been rectified and all delegated authorising officers were instructed that they must take care to sign the right transaction (in SI2) based on the delegation decision and that they must act with due diligence in this regard. The CSS expenditure for 2006 will be included in the EMEA budget with the first Amending Budget and the costs will be charged to the members. Disclosure of the CSS activities in 2005 has been made in note 4 of the EMEA 2005 Accounts. The composition of evaluation committees, often made up of more than three persons, is based on the principle that bids should be evaluated by persons both independent and with appropriate expertise. In any case, a minimum of three persons participate to the meetings and the minutes for each meeting are distributed for discussion and approval. In the future, the Agency will request that minutes include a justification in case of absence of a member. Lastly, in 2006, the Agency launched a tender for banking services. The delay mentioned by the Court is due to the fact that over the last years, the financial system of the Agency has been overhauled and it would have been too disruptive to implement a change of bank. type: Court of Auditors: opinion, report body: CofA
  • date: 2007-02-07T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=5711%2F07&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 05711/2007 summary: Having examined the revenue and expenditure account for the financial year 2005, the balance sheet of revenue and expenditure at 31 December 2005 of the European Medicines Agency, the Council recommends the European Parliament to give a discharge to the Director of the Agency in respect of the implementation of the budget for the financial year 2005. In doing so, the Council confirms that EUR 21.6 million (95%) of the EUR 22.7 million in appropriations carried forward from the financial year 2004 to the financial year 2005 have been used. In addition, EUR 18.8 million in appropriations have been carried forward from the financial year 2005 to the financial year 2006 and EUR 5.6 million have been cancelled. In parallel, the Council makes accompanying comments on the discharge which should be followed up. In particular, it: shares the Court's observation on the high carry-over rate for administrative expenditure in 2004-2005 and calls on the Agency to comply with the principle of annuality; calls on the Agency to respect the rules on the award of contracts, especially as regards IT contracts; shares the Court's opinion on the need to start a new call for tender regarding the services provided by banks and notes from the Agency's reply that this is the case. type: Supplementary non-legislative basic document body: CSL
  • date: 2007-02-09T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE384.440 title: PE384.440 type: Committee draft report body: EP
  • date: 2007-02-28T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE382.438&secondRef=02 title: PE382.438 committee: ENVI type: Committee opinion body: EP
  • date: 2007-03-08T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE386.407 title: PE386.407 type: Amendments tabled in committee body: EP
  • date: 2007-03-30T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2007-99&language=EN title: A6-0099/2007 type: Committee report tabled for plenary, single reading body: EP
  • date: 2007-05-31T00:00:00 docs: url: /oeil/spdoc.do?i=13464&j=0&l=en title: SP(2007)2625/2 type: Commission response to text adopted in plenary
events
  • date: 2006-10-31T00:00:00 type: Non-legislative basic document published body: EC docs: title: N6-0029/2006 summary: PURPOSE: presentation of the final accounts of the European Medicines Agency for the financial year 2005. CONTENT: this document published in the Official Journal of the EU sets out a detailed account of the implementation of the 2005 budget, including the revenue and expenditure and the balance sheet for the year concerned. According to this document, the final budget amounted to EUR 111.8 million (in comparison to EUR 99.4 million in 2004) consisting of a 22.7% Community contribution. As regards staffing, the Agency, whose headquarters are based in London (UK), set out a total of 379 posts in the establishment plan. 337.5 posts are currently occupied + 34 other posts (auxiliary contracts, seconded national experts, local staff, employment agency staff) totalling 317.5 posts (340 in 2004) assigned to operational, administrative and mixed tasks. Staff expenditure accounted for EUR 41.356 million. Throughout 2005, the Agency concentrated on coordinating the scientific evaluation of medicinal products which are subject to Community marketing authorisation procedures. Concerning medicinal products for human use, the Agency: - replied to 43 applications for marketing authorisations and delivered 24 favourable opinions taking an average evaluation time of 203 days as opposed to 187 days in 2004; - delivered 1 148 opinions after authorisation; - drafted 91 565 pharmacovigilance reports (64 186 in 2004) and 279 periodic reliability reports; - delivered 135 scientific opinions and 8 451 procedures for mutual recognition. Concerning veterinary medicinal products, the Agency: - replied to 11 new applications for marketing authorisations and 70 applications in respect of variants; - carried out 114 inspections. As regards orphan medicinal products, the Agency: - replied to 118 applications and gave 88 favourable opinions. The complete version of the final accounts may be found at the following address: www.emea.eu.int
  • date: 2006-11-29T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
  • date: 2007-03-26T00:00:00 type: Vote in committee, 1st reading/single reading body: EP summary: The committee adopted the report by Edit HERCZOG (PES, HU) granting discharge to the the European Medicines Agency for 2005. In its accompanying resolution, it made a number of general points concerning the majority of the EU agencies: - the ever-growing number of Community Agencies and the activities of some of them do not seem to form part of an overall policy framework, and "the remits of some Agencies do not always reflect the real needs of the Union or the expectations of its citizens”; - the Commission should therefore define an overall policy framework and should present a cost-benefit study before the setting up of any new Agency, and the Court of Auditors should give its opinion on this study before Parliament takes its decision; - every 5 years, the Commission should present a study on the added value of every existing Agency; where the evaluation is negative in the case of a particular Agency the latter’s mandate should be reformulated or the Agency should be closed; - the Commission should improve administrative and technical support to the Agencies, given the growing complexity of the Community’s administrative rules and technical problems; - the Agencies should improve their cooperation and benchmarking with actors in the field; - the Commission should harmonise the format of the annual reporting by the Agencies to develop performance indicators which would allow a comparison of their efficiency. In its specific remarks concerning the EMA, the committee welcomed the increased appropriations for and full implementation of the Orphan Drugs budget line. It pointed out that the new pharmaceuticals legislation adopted in 2004 had had a considerable impact on the Agency's work, management structures and staff, and it welcomed the Agency's efforts to provide more scientific advice at early stages of the development of new medicines. It also noted the Agency's work in facilitating a quick assessment of vaccines in the event of an influenza pandemic. Lastly, the committee asked the Agency, before 1 January 2010 and every 5 years thereafter, to commission an independent external evaluation of its achievements on the basis of its founding Regulation and the work programmes decided by the Management Board. In the light of this evaluation, the Board should draft "such recommendations to the Commission and Parliament as may be necessary regarding changes in the Agency, its working practices and programmes".
  • date: 2007-03-30T00:00:00 type: Committee report tabled for plenary, single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2007-99&language=EN title: A6-0099/2007
  • date: 2007-04-24T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=13464&l=en title: Results of vote in Parliament
  • date: 2007-04-24T00:00:00 type: Debate in Parliament body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20070424&type=CRE title: Debate in Parliament
  • date: 2007-04-24T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P6-TA-2007-120 title: T6-0120/2007 summary: The European Parliament adopted a resolution drafted by Edit HERCZOG (PSE, HU), and granted the executive director of the European Medicines Agency discharge for the implementation of the Agency's budget for the financial year 2005. It then approved the closing of the accounts of the Centre for the financial year 2005. The Parliamentary resolution is divided into two parts. The first contained general points, and concerned the majority of EU Agencies requiring individual discharge. The second part contained specific points relating to the Agency. General points: Parliament considers that the ever-growing number of Community Agencies and the activities of certain of them do not seem to form part of an overall policy framework, and that the remits of some Agencies do not always reflect the real needs of the Union. Accordingly, it invites the Commission to define an overall policy framework for the setting up of new Community Agencies and to present a cost-benefit study before the setting up of any new agency, while being careful to avoid any overlap of activities between Agencies or with the remits of other European organisations. Parliament calls on the Court of Auditors to give its opinion on this cost-benefit study before Parliament takes its decision, and it asks the Commission to present every five years a study on the added value of every existing Agency. ; invites all relevant institutions In the case of a negative evaluation of the added value of an Agency, all relevant institutions are asked to take the necessary steps by reformulating the mandate of that Agency or by closing it. In view of the constantly increasing number of Agencies, Parliament feels that the Directorates-General of the Commission charged with the setting up and monitoring of Agencies must develop a common approach to the Agencies. It also asks the Commission to improve administrative and technical support to the Agencies. Parliament regretted that the negotiations on the draft interinstitutional agreement on the operating framework for the European regulatory agencies have not yet been concluded, and calls on the Commission, in consultation with the Court of Auditors, to do their utmost to ensure that the agreement is brought to a rapid conclusion. Noting that the Commission's budgetary responsibility calls for closer linking of the Agencies to the Commission, Parliament calls on the Commission and the Council to take all necessary steps to give the Commission a blocking minority in the supervisory bodies of the regulatory Agencies by 31 December 2007 and to provide for such a minority from the outset when new Agencies are set up. It invites the Court of Auditors to create an additional chapter in its Annual Report, devoted to all Agencies to be discharged under the Commission's accounts in order to have a much clearer picture of the use of EU funds by Agencies. Parliament goes on to ask the Commission to come up with a proposal to harmonise the format of the annual reporting by the Agencies and to develop performance indicators which would allow a comparison of their efficiency. The Commission is urged to monitor and direct the management of the Agencies, especially in relation to the proper application of tender procedures, transparency of recruitment procedures, sound financial management and, most importantly, the proper application of the rules concerning the internal control framework. Specific points concerning the European Medicines Agency: Parliament noted that for administrative expenditure (Title II) the utilisation rate for commitment appropriations was less than 90 %, with more than 40 % of the commitments made being carried over to the following financial year. It also noted that the budget of the Agency has grown considerably between 2003 and 2005 due to the enlargement of the EU and new tasks, and pronounced itself very pleased with the increased appropriations for, and the full implementation of, the Orphan Drugs budget line. Parliament invited the Agency to make sure that only staff members with delegation rights have access to the corresponding computer system. It demanded that contract award procedures should be transparent and follow the guiding rules including in the IT area, and it asked the Agency to inform Parliament about the new call for tender concerning bank contracts according to standard rules as soon as possible. Parliament went on to point out that the new pharmaceuticals legislation, adopted in 2004, has had a considerable impact on the Agency's work, management structures and staff, congratulating the Agency on successfully adapting to the new regulatory framework. It welcomed the Agency’s efforts to provide more scientific advice at early stages of the development of new medicines as well as the introduction of measures to accelerate the assessment of medicines that are of critical importance to public health, noting the work done by the Agency to facilitate a quick assessment of vaccines in the event of an influenza pandemic. Lastly, Parliament wanted the Agency to commission an independent external evaluation of its achievements before 1 January 2010 and every five years thereafter. The Agency should draft such recommendations to the Commission and Parliament as may be necessary regarding changes in the Agency. The evaluation and the recommendations must be made public.
  • date: 2007-04-24T00:00:00 type: End of procedure in Parliament body: EP
  • date: 2008-07-15T00:00:00 type: Final act published in Official Journal summary: PURPOSE: to grant discharge to the European Medicines Agency for the financial year 2005. LEGISLATIVE ACT: Decision 2008/521/EC of the European Parliament on the discharge for the implementation of the budget of the European Medicines Agency for the financial year 2005. CONTENT: with the present decision, the European Parliament grants discharge to the Executive Director of the European Medicines Agency for the implementation of the Agency’s budget for the financial year 2005. This decision is in line with the European Parliament’s resolution adopted on 24 April 2007 and comprises a series of observations that form an integral part of the discharge decision (please refer to the summary of the opinion of 24/04/2007). docs: title: Budget 2008/521 url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B[%g]-2008-521&language=EN title: OJ L 187 15.07.2008, p. 0128 url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2008:187:SOM:EN:HTML
links
other
  • body: EC dg: url: http://ec.europa.eu/dgs/budget/ title: Budget commissioner: KALLAS Siim
procedure/dossier_of_the_committee
Old
CONT/6/42413
New
  • CONT/6/42413
procedure/legal_basis/0
Rules of Procedure EP 94
procedure/legal_basis/0
Rules of Procedure of the European Parliament EP 094
procedure/subject
Old
  • 8.70.03.07 Previous discharges
New
8.70.03.07
Previous discharges
activities/6/docs/1/url
Old
http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2008:187:TOC
New
http://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2008:187:SOM:EN:HTML
activities
  • date: 2006-10-31T00:00:00 docs: type: Non-legislative basic document published title: N6-0029/2006 type: Non-legislative basic document published body: EC commission: DG: url: http://ec.europa.eu/dgs/budget/ title: Budget Commissioner: KALLAS Siim
  • date: 2006-11-29T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: CONT date: 2006-04-20T00:00:00 committee_full: Budgetary Control rapporteur: group: PSE name: HERCZOG Edit body: EP responsible: False committee: ENVI date: 2006-09-14T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PSE name: HAUG Jutta
  • date: 2007-02-27T00:00:00 body: CSL type: Council Meeting council: Economic and Financial Affairs ECOFIN meeting_id: 2787
  • date: 2007-03-26T00:00:00 body: EP committees: body: EP responsible: True committee: CONT date: 2006-04-20T00:00:00 committee_full: Budgetary Control rapporteur: group: PSE name: HERCZOG Edit body: EP responsible: False committee: ENVI date: 2006-09-14T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PSE name: HAUG Jutta type: Vote in committee, 1st reading/single reading
  • date: 2007-03-30T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2007-99&language=EN type: Committee report tabled for plenary, single reading title: A6-0099/2007 body: EP type: Committee report tabled for plenary, single reading
  • date: 2007-04-24T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=13464&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20070424&type=CRE type: Debate in Parliament title: Debate in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P6-TA-2007-120 type: Decision by Parliament, 1st reading/single reading title: T6-0120/2007 body: EP type: Results of vote in Parliament
  • date: 2008-07-15T00:00:00 type: Final act published in Official Journal docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=MOTION&reference=B[%g]-2008-521&language=EN title: Budget 2008/521 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2008:187:TOC title: OJ L 187 15.07.2008, p. 0128
committees
  • body: EP responsible: True committee: CONT date: 2006-04-20T00:00:00 committee_full: Budgetary Control rapporteur: group: PSE name: HERCZOG Edit
  • body: EP responsible: False committee: ENVI date: 2006-09-14T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PSE name: HAUG Jutta
links
other
  • body: EC dg: url: http://ec.europa.eu/dgs/budget/ title: Budget commissioner: KALLAS Siim
procedure
dossier_of_the_committee
CONT/6/42413
reference
2006/2161(DEC)
title
2005 discharge: European Agency for the Evaluation of Medicinal Products
legal_basis
Rules of Procedure of the European Parliament EP 094
stage_reached
Procedure completed
type
DEC - Discharge procedure
final
subject
8.70.03.07 Previous discharges